Latest filing published 15 Apr 2026 for 동성제약, €5.8M.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by 태광산업 span 3 companies, the busiest being 동성제약, 애경산업 and 태광산업. We count 6 filings; the first trade dates from 13 March 2026 and the latest from 9 April 2026.
Every open-market trade on record is a purchase: 3 purchases worth €151.0M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The median purchase comes to €17.3M. As a share of market capitalisation, the median purchase stands at 16.4%, based on 3 purchases. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of +0.0%. These figures describe past trades and do not predict future prices.
The newest entry dates from 15 April 2026: an open-market purchase of €5.8M, in 동성제약. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations